The BA.2 subtype of the Omicron coronavirus variant appears to have a substantial growth advantage over the currently predominant BA.1 type, Britain’s UK Health Security Agency said on Jan. 28.
If you are not happy with the results below please do another search
50 search results for:
Provention Bio is resubmitting a Biologics License Application (BLA) for teplizumab, a drug intended to delay the onset of Type 1 diabetes (T1D) in at-risk individuals, following a Type B pre-BLA resubmission meeting with the U.S. Food and Drug Administration.
Biogen is selling the company’s nearly 50 percent stake in South Korea-based Samsung Bioepis for $2.3 billion.
Eli Lilly said on Jan. 28 the company expects the U.S. Food and Drug Administration to decline the approval of expanded use of the rheumatoid arthritis drug Olumiant as a treatment for adults with moderate-to-severe eczema.
Regeneron Pharmaceuticals and the company’s partner Sanofi voluntarily withdrew their application with the U.S. drug regulator for the expanded use of the anti-cancer drug Libtayo in patients with advanced cervical cancer.
Merck & Co. Inc. and partner Ridgeback Biotherapeutics said on Jan. 28 six lab studies showed their experimental oral COVID-19 drug molnupiravir was active against the fast-spreading Omicron variant.
A $2.1 million grant from the National Institutes of Health will allow University of Arizona Health Sciences researchers to study the links between knee structure changes and clinical outcomes in people with osteoarthritis.
This whitepaper covers the role that the BMC Helix portfolio can play in helping healthcare organizations to modernize their infrastructure and drive digital transformation.
Kate Rawson, one of the most insightful and practical observers of the health policy scene in Washington, offers the Coalition for Healthcare Communication her well-informed analysis and a Q&A format.
On the strength of data from Alzamend Neuro’s Phase I study of its lead compound AL001 being developed for the treatment of Alzheimer’s disease, the company is looking to commence a Phase II multiple ascending dose study for that indication during the second quarter of 2022.